首页> 美国卫生研究院文献>Aging (Albany NY) >Identification of SYK inhibitor R406 as a novel senolytic agent
【2h】

Identification of SYK inhibitor R406 as a novel senolytic agent

机译:鉴定SYK抑制剂R406为新型的抗衰老药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The selective removal of senescent cells by senolytics is suggested as a potential approach to reverse aging and extend lifespan. Using high-throughput screening with replicative senescence of human diploid fibroblasts (HDFs), we identified a novel senolytic drug R406 that showed selective toxicity in senescent cells. Using flow cytometry and caspase expression analysis, we confirmed that R406 caused apoptotic cell death along with morphological changes in senescent cells. Interestingly, R406 altered the cell survival-related molecular processes including the inhibition of phosphorylation of the focal adhesion kinase (FAK) and p38 mitogen-activated protein kinase (MAPK) in senescent cells. This pattern was not observed in other known senolytic agent ABT263. Correspondingly, apoptotic cell death in senescent cells was induced by simultaneously blocking the FAK and p38 pathways. Taken together, we suggest that R406 acts as a senolytic drug by inducing apoptosis and reducing cell attachment capacity.
机译:建议通过senolytics选择性去除衰老细胞,作为逆转衰老和延长寿命的潜在方法。使用高通量筛选人类二倍体成纤维细胞(HDFs)的复制衰老,我们鉴定了一种新型的衰老药物R406,在衰老细胞中显示选择性毒性。使用流式细胞仪和胱天蛋白酶表达分析,我们证实R406引起凋亡的细胞死亡以及衰老细胞的形态变化。有趣的是,R406改变了与细胞存活相关的分子过程,包括抑制衰老细胞中粘着斑激酶(FAK)和p38丝裂原活化蛋白激酶(MAPK)的磷酸化。在其他已知的镇静剂ABT263中未观察到此模式。相应地,通过同时阻断FAK和p38途径诱导衰老细胞的凋亡。两者合计,我们建议R406通过诱导凋亡和降低细胞附着能力,作为一种抗衰老药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号